Flatiron Health, a health tech company in oncology, and Lifebit Biotech, a UK-based biotech firm, are expanding their collaboration into Japan to improve cancer care through real-world data (RWD).

Lifebit's federated Trusted Research Environment (TRE) technology will enable secure access to Flatiron Health's oncology RWD, allowing researchers to analyze data without removing it from the secure environment. This collaboration aims to facilitate cross-market insights and advance oncology research while maintaining high levels of data governance and privacy protection.

The partnership will initially focus on datasets for gastric, colorectal, and breast cancer in Japan. Flatiron Health plans to present findings from a study on early-onset gastric and colorectal cancer in Japan and the US at the upcoming Asian Conference of Pharmacoepidemiology, demonstrating the potential of this collaboration to generate impactful evidence across markets.

Analyst QuickTake: This marks the fourth partnership Flatiron Health has entered in 2024. In March 2024 , it partnered with the Medical University of South Carolina (MUSC) to bring Flatiron's oncology-specific clinical decision support platform, Flatiron Assist, to MUSC's Hollings Cancer Center. Before this, in April 2024 , the company partnered with the National Comprehensive Cancer Network (NCCN) to utilize real-world data to improve cancer care and research. More recently, in May 2024 , the company partnered with the Association of Cancer Care Centers (ACCC) to improve access to oncology-related clinical trials and refine clinical study data collection.